Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2066 in Major Depressive Disorder
NCT01145755Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- May 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD-2066 in major depressive disorder (MDD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Montgomery-Åsberg Depression Rating Scale Total Score Change From Baseline at 6 weeks. Started May 2010; status: terminated.
02
Drugs
AZD-2066
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01145755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01145755.